This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Hand and foot dermatitis
  • /
  • Topical Ruxolitinib Evaluation in Chronic Hand Ecz...
Clinical trial

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Read time: 1 mins
Last updated:12th Jun 2024
Identifier: NCT05906628
Topical Ruxolitinib Evaluation in Chronic Hand Eczema ID: NCT05906628

Sponsor: Incyte Corporation
Information provided by: Incyte Corporation (Responsible Party)
Last Update Posted: 2024-04-10

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

Official Title:
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema

Intervention / Treatment: 
Drug: Ruxolitinib cream
Drug: Vehicle

Category Value
Study Start (Actual) 2023-07-31
Primary Completion (Estimated) 2024-08-26
Study Completion (Estimated) 2025-01-17
Enrollment (Actual) 186
Study Type Interventional
Phase Phase 2
Other Study ID Numbers
INCB 18424-226

2022-502827-23-00 (Registry Identifier) (REGISTRY: EU CT Number)

View full details